<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405196</url>
  </required_header>
  <id_info>
    <org_study_id>B0151006</org_study_id>
    <secondary_id>2011-000420-15</secondary_id>
    <secondary_id>BUTTERFLY</secondary_id>
    <nct_id>NCT01405196</nct_id>
  </id_info>
  <brief_title>Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus</brief_title>
  <acronym>BUTTERFLY</acronym>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Multicenter Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-04236921 In Subjects With Systemic Lupus Erythematosus (Sle)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate and compare efficacy of 3 dose levels of
      PF-04236921 to placebo in subjects with generalized lupus using a measure called the Systemic
      Lupus Erythematosus (SLE) Responder Index. The study will evaluate secondary and exploratory
      measures as well.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>SRI components include:Systemic Lupus Erythematosus Disease Activity Index 2000(SLEDAI-2K),British Isles Lupus Assessment Group(BILAG) 2004,Physician's Global Assessment(PhGA).Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: greater than or equal to(&gt;=) 4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening (less than [&lt;] 0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids,immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. SLEDAI-2K:assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG:assesses disease extent, severity (range: A[severe] to E[no disease]). PhGA: assesses worsening in participant's general health status(range: 0[none] to 3[severe]).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 4, 8, 12, 16, and 20</measure>
    <time_frame>Week 4, 8, 12, 16, 20</time_frame>
    <description>SRI components include:SLEDAI-2K ,BILAG 2004, PhGA. Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: &gt;=4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening (&lt;0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids,immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG:assesses disease extent, severity (range: A [severe] to E [no disease]). PhGA: assesses worsening in participant's general health status(range: 0[none] to 3[severe]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Modified Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 4, 8, 12, 16, 20, and 24</measure>
    <time_frame>Week 4, 8, 12, 16, 20, 24</time_frame>
    <description>SRI components include: modified SLEDAI-2K (SLEDAI-2K without standard parameters &quot;Low complement&quot; and &quot;Leukopenia&quot;), BILAG 2004, PhGA. Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: &gt;=4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening (&lt;0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids, immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. Modified SLEDAI-2K: assesses improvement in disease activity (range: 0 to 102; higher score = higher severity). BILAG: assesses disease extent, severity (range: A [severe] to E [no disease]). PhGA: assesses worsening in participant's general health status (range: 0[none] to 3[severe]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response at Week 4, 8, 12, 16, 20, and 24</measure>
    <time_frame>Week 4, 8, 12, 16, 20, 24</time_frame>
    <description>BICLA include: BILAG-2004, SLEDAI-2K, PhGA of disease activity. Participants classified as responder if they did not meet the definition of treatment failure and met all the following criteria: BILAG-2004 improvement (all A scores at baseline improved to B/C/D and all B scores improved to C or D); no worsening in disease activity (no new BILAG-2004 A scores or =&lt;1 new B score); no worsening of total SLEDAI-2K score; no significant deterioration (&lt;10 percent [%] worsening) in analogue PhGA. Treatment failure: any new/increased use of corticosteroids,immunosuppressants/antimalarial, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. BILAG:assesses disease extent, severity (range: A[severe] to E[no disease]). SLEDAI-2K:assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). PhGA: assesses worsening in participant's general health status(range: 0[none] to 3[severe]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Pre-defined Criteria for Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Components at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>SRI components include: SLEDAI-2K, BILAG 2004 and PhGA. Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: &gt;=4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening(&lt;0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids, immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. SLEDAI-2K: assesses improvement in disease activity(range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity (range: A[severe] to E [no disease]). PhGA: assesses worsening in participant's general health status (range: 0[none] to 3[severe]). Model percent estimates reported only for 'Reduction in SLEDAI Score','No Worsening in PhGA' categories; for remaining categories, raw percentages reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Laboratory Tests Results</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Pre-defined criteria were established for each laboratory test to define the values that would be identified as of potential clinical importance. Laboratory values included Alanine Aminotransferase (ALT) [&gt;5.0 - 10.0*Upper limit of normal range (ULN)], Albumin [&lt;26-20 gram per liter (g/L)/ &lt;20 g/L], Amylase [&gt;2.0 - 5.0*ULN], Aspartate Aminotransferase (AST) [&gt;5.0 - 10.0*ULN], Creatine Kinase (CK) [&gt;5.0 - 10.0* ULN/ &gt;10.0*ULN], Glucose (Hyperglycemia) [&gt;13.9 - 27.8 millimoles/liter (mmol/L)], Hemoglobin (HGB) [&lt;80 - 65 g/L/ &lt;65 g/L], Lipase [&gt;2.0 - 5.0*ULN], Lymphocytes (Lymph.)(Absolute [Abs]) [&lt;0.5 - 0.2*10^3/microliter (UL)/ &lt;0.2*10^3/UL], Platelets [&lt;50-25*10^3/UL/ &lt;25*10^3/UL], potassium (low) [&lt;3.0 - 2.5 mmol/L], Sodium (low) [&lt;130 - 120 mmol/L], Total Neutrophils (TN) (Abs) [&lt;1.0 - 0.5*10^3/UL/ &lt;0.5*10^3/UL], Triglycerides [&gt;5.7 - 11.4 mmol/L], White Blood Cell Count (WBC) [&lt;2.0 - 1.0*10^3/UL/ &lt;1.0*10^3/UL].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Due to Adverse Events</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Number of participants who discontinued due to adverse events were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 52 that were absent before treatment or that worsened relative to pretreatment state. Number of participants with treatment-emergent AEs or SAEs (excluding infectious AEs or SAEs and injection site reactions) were reported. AEs include both SAEs and non-SAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Infectious Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 52 that were absent before treatment or that worsened relative to pretreatment state. Number of participants with treatment-emergent infectious AEs or SAEs were reported. AEs include both SAEs and non-SAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Potentially Clinically Important (PCI) Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Criteria for potentially clinically important (PCI) findings in ECG were defined as: heart rate &lt;=40 beats per minute (bpm) or &gt;=120 bpm; PR interval &gt;=220 millisecond (msec); QT interval &gt;=480 msec; QRS interval &gt;=120 msec; QT interval corrected using the Fridericia formula (QTcF) &gt;=500msec; no sinus rhythm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Potentially Clinically Important Vital Signs Findings</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Criteria for PCI findings in vital signs were defined as: sitting systolic blood pressure (Increase from baseline &gt;=20 millimeter of mercury (mm Hg) and &gt;=160 mm Hg or a decrease from baseline &gt;=20 mm Hg and &lt;=90 mm Hg) and sitting diastolic blood pressure (increase from baseline &gt;=15 mm Hg and &gt;=90 mm Hg or decrease from baseline &gt;=15 mm Hg and &lt;=60 mm Hg), pulse rate (increase from baseline &gt;=15 beats/min and &gt;=120 beats/min or decrease from baseline &gt;=15 beats/min and &lt;=50 beats /min), body temperature (increase of &gt;=2 degree Fahrenheit (F) and temperature &gt;=101 degree F) and weight (change of &gt;=7% in body weight)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-drug Antibodies (ADAs) and Neutralizing Antibodies (Nabs)</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Human serum samples were analyzed for the presence or absence of anti-PF-04236921 antibodies. A positive ADA sample was further tested for neutralizing antibodies using a validated assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of PF-04236921</measure>
    <time_frame>Day 1, Week 2, 4, 6, 8, 12, 16, 20, 24</time_frame>
    <description>Serum PF-04236921 concentrations over time were summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Corticosteroid Dose Reduced by Both Greater Than or Equal to (&gt;=) 25 Percent (%) From Baseline and Less Than or Equal to (&lt;=) 7.5 Milligrams Per Day (mg/Day)</measure>
    <time_frame>Week 12, 16, 20, 24</time_frame>
    <description>Participants were given supplemental corticosteroids at baseline to control disease activity, if necessary. The steroid taper was based on participant's symptoms. Participants recorded their steroid usage on a diary card. Least Observation Carried Forward (LOCF) method was used to impute missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normalized Serological Activity</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Serologic activity was to be assessed in the subgroup of participants who had positive serologic activity at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Visual Analog Scale (VAS) Scores at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Participants assessed their disease activity using a 100 millimeter (mm) VAS. Participants answered the following question &quot;Considering all the ways your disease affects you, how are you feeling today?&quot; Response was recorded by placing a mark on the scale between 0 (very well) and 100 (extremely bad).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24</measure>
    <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24</time_frame>
    <description>Participants assessed their disease activity using a 100 mm VAS. Participants answered the following question &quot;Considering all the ways your disease affects you, how are you feeling today?&quot; Response was recorded by placing a mark on the scale between 0 (very well) and 100 (extremely bad).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24</measure>
    <time_frame>Baseline, Week 4, 8, 12, 16, 20, 24</time_frame>
    <description>EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point VAS (0= worst imaginable health state, 100= best imaginable health state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thirty Six-Item Short-Form Health Survey (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as PCS and mental component score MCS. The score for each aspect and PCS/MCS is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24</measure>
    <time_frame>Baseline, Week 4, 8, 12, 16, 20, 24</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical component score (PCS) and mental component score (MCS). The score for each aspect and PCS/MCS is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vitality Scores at Week 4, 8, 12, 16, 20 and 24</measure>
    <time_frame>Baseline, Week 4, 8, 12, 16, 20, 24</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Vitality sub-score is a component of SF-36 Health Survey Questionnaire and assesses energy and fatigue. The vitality score ranged from 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24</measure>
    <time_frame>Baseline, Week 4, 8, 12, 16, 20, 24</time_frame>
    <description>The SF-6D focuses on seven of the eight health domains covered by the SF-36 Health Survey: physical functioning, role participation (combined role-physical and role-emotional), social functioning, bodily pain, mental health, and vitality. The SF-6D is an attempt to derive a single index from the SF-36 Health Survey for use in economic evaluation studies. As such, it represents a summary score based on a subset of the SF-36 data. Consequently, in lieu of the SF-6D, PCS and MCS SF-36 results are being provided. The score for each aspect and PCS/MCS is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24</measure>
    <time_frame>Baseline, Week 4, 8, 12, 16, 20, 24</time_frame>
    <description>FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). LOCF method was used to impute missing values.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <arm_group>
    <arm_group_label>10 mg of PF-04236921</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg of PF-04236921</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg of PF-04236921</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04236921</intervention_name>
    <description>subcutaneous injection; administered at day 1, weeks 8, 16.</description>
    <arm_group_label>10 mg of PF-04236921</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04236921</intervention_name>
    <description>subcutaneous injection; administered at day 1, weeks 8, 16.</description>
    <arm_group_label>50 mg of PF-04236921</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04236921</intervention_name>
    <description>subcutaneous injection; administered at day 1, weeks 8, 16.</description>
    <arm_group_label>200 mg of PF-04236921</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04236921</intervention_name>
    <description>subcutaneous injection; administered at day 1, weeks 8, 16</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects between ages of 18 and 75 years old at time of signing
             consent.

          -  Have a clinical diagnosis of SLE according to 1997 update on the revised 1982 American
             College of Rheumatology (ACR) criteria.

          -  Have a unequivocally positive anti-nuclear antibody (ANA) test result.

          -  Active disease at screening defined by both: SLEDAI-2K score greater than or equal to
             6 and BILAG Level A disease in more than or equal to 1 organ system (except renal or
             central nervous system) or BILAG B disease in more than or equal to 2 organ systems if
             no level A disease in present.

        Exclusion Criteria:

          -  Any prior history of treatment with PF-04236921, or anti-IL-6 agent;

          -  Have received any of the following within 364 days of day 1: a biologic
             investigational agent other than B cell targeted therapy; required 3 or more courses
             of systemic corticosteroids for concomitant conditions; history of previously
             untreated or current evidence of active or untreated latent infection with
             Tuberculosis (TB), evidence of prior untreated or currently active TB by chest
             radiography, residing with or frequent close contact with an individual with active
             TB.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anniston Medical Clinic, PC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Research Group, LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Investigations, Inc.</name>
      <address>
        <city>Fair Oaks</city>
        <state>California</state>
        <zip>95628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research, LLC</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wallace Rheumatic Study Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Division of Rheumatology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Rheumatology Clinical Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-6984</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Rheumatology and Osteoporosis Medical Group</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Rheumatology Clinical Trials, Inc.</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma, Allergy, Arthritis and Lung Center</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Arthritis Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Community Pharmacy</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Integrated Medical, PL, d/b/a Florida Medical Research Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern lmaging &amp; Diagnostics</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Horizon Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Associates</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Center</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advent Clinical Research Centers, Inc.</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burnette &amp; Silverfield, MDS PLC</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Health Systems</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho Arthritis Center</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beacon Medical Group Rheumatology</name>
      <address>
        <city>Granger</city>
        <state>Indiana</state>
        <zip>46530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana CTSI Clinical Research Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Drug Services</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Outpatient Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Outpatient Express Testing Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center/ Center for Arthritis and Rheumatic Diseases</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System,</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5872</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System (Henry Ford Medical Center)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-3450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shores Rheumatology P.C</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nevada School of Medicine</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteoporosis Medical Associates, PLLC</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Feinstein Institute for Medical Research</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Center for Musculoskeletal Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy/Immunology and Rheumatology</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina Clinical and Translational Research Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina Hospitals Investigational Drug Services</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint and Muscle Medical Care</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Arthritis &amp; Rheumatology of the Carolinas, PLLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research and Consulting, LLC</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Medical Research Foundation</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Reading, LLP</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Low Country Rheumatology, PA/Low Country Research</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tennessee Research Institute</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8577</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatic Disease Clinical Research Center, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Rheumatology Research, LLC</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Seattle Arthritis Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tacoma Center for Arthritis Research, PS</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain State Clinical Research</name>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <zip>26301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Framingham Centro Medico</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>B1902COS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto CAICI S.R.L.</name>
      <address>
        <city>Rosario</city>
        <state>Santa FE</state>
        <zip>S2000PBJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Privado de Reumatologia</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Educación Medica e Investigaciones Clinicas &quot;Norberto Quirno&quot; CEMIC</name>
      <address>
        <city>C.a.b.a</city>
        <zip>C1431FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Polivalente de Asistencia e Investigación Clínica - CER- San Juan</name>
      <address>
        <city>San Juan</city>
        <zip>J5402DIL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedad Medica del Aparato Locomotor S.A. (SOMEAL)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <zip>7510186</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios Reumatologicos</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>7501126</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Prosalud</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mix Supplier S.A.</name>
      <address>
        <city>Envigado</city>
        <state>Antioquia, Colombia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral de Reumatologia REUMALAB S.A.S.</name>
      <address>
        <city>Envigado</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>0</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral de Reumatología del Caribe CIRCARIBE SAS</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Congregacion de Hermanas Franciscanas Misioneras de Maria Auxiliadora- Clinica Asunción</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Organizacion Clinica General del Norte S.A.</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farmamix Ltda.</name>
      <address>
        <city>Bogota, Distrito Capital</city>
        <state>Cundimarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral de Reumatologia e Inmunologia S.A.S.- CIREI S.A.S.</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riesgo De Fractura S.A</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servimed E.U</name>
      <address>
        <city>Bucaramanga</city>
        <state>Santander</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farmamix Ltda.</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitaetsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité University Medicine Berlin. Schlosspark-Klinik</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIRI am Klinikum der Goethe-Universitaet</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig AoeR, Department fuer Innere Medizin</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qualiclinic Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Orvos és Egeszsegtudomanyi Centrum</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kepviselo-testulet Pandy Kalman Korhaz Infektologia, Hepatologia es Immunologia</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Medical Center 1</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Republican</name>
      <address>
        <city>Chisinau</city>
        <state>Md-2025</state>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion REUMED, Clinica Anglo Americana</name>
      <address>
        <city>San Isidro</city>
        <state>Lima</state>
        <zip>Lima 27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigaciones Clínicas SAC</name>
      <address>
        <city>Santiago de Surco</city>
        <state>Lima</state>
        <zip>Lima 33</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigaciones Clinicas SAC</name>
      <address>
        <city>Surco</city>
        <state>Lima</state>
        <zip>Lima 33</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigación en Medicina Interna y Enfermedades Críticas</name>
      <address>
        <city>Arequipa</city>
        <zip>AQ 54</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Reumatologiczne Indywidualna Specjalistyczna Praktyka Lekarska lek.med. Barbara Bazela</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medyczne Centrum Hetmanska - Indywidualna Specjalistyczna Praktyka Lekarska -</name>
      <address>
        <city>Poznan</city>
        <zip>60-218</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatna Praktyka Lekarska Prof. UM Dr hab. med. Pawel Hrycaj</name>
      <address>
        <city>Poznan</city>
        <zip>61-397</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Rheumatology, Allergy and Immunology</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Sf. Maria</name>
      <address>
        <city>Bucuresti</city>
        <zip>11172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Colentina</name>
      <address>
        <city>Bucuresti</city>
        <zip>20125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Jedetean de urgenta Cluj, Reumatologie</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta &quot;Sf. Apostol Andrei&quot;</name>
      <address>
        <city>Galati</city>
        <zip>800578</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei TOC</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Moldova, Republic of</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Mexico</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0151006&amp;StudyName=Subcutaneous%20Treatment%20In%20Randomized%20Subjects%20To%20Evaluate%20Safety%20And%20Efficacy%20In%20Generalized%20Lupus%20Erythematosus%0A%20%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2011</study_first_submitted>
  <study_first_submitted_qc>July 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <results_first_submitted>November 18, 2016</results_first_submitted>
  <results_first_submitted_qc>December 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2017</results_first_posted>
  <disposition_first_submitted>December 14, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>December 14, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 14, 2016</disposition_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>double-blind</keyword>
  <keyword>placebo-controlled</keyword>
  <keyword>multicenter</keyword>
  <keyword>dose-ranging</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>lupus.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Due to safety reason, dosing in 200 mg reporting arm was prematurely terminated and the participants were discontinued from it. Therefore, the statistical analysis plan was amended after it and 200 mg reporting arm was not included in efficacy data analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PF-04236921 10 Milligram (10 mg)</title>
          <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
        </group>
        <group group_id="P2">
          <title>PF-04236921 50 mg</title>
          <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
        </group>
        <group group_id="P3">
          <title>PF-04236921 200 mg</title>
          <description>Participants received 200 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PF-04236921 10 Milligram (10 mg)</title>
          <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
        </group>
        <group group_id="B2">
          <title>PF-04236921 50 mg</title>
          <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
        </group>
        <group group_id="B3">
          <title>PF-04236921 200 mg</title>
          <description>Participants received 200 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="46"/>
            <count group_id="B4" value="45"/>
            <count group_id="B5" value="183"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.9" spread="11.48"/>
                    <measurement group_id="B2" value="38.3" spread="10.49"/>
                    <measurement group_id="B3" value="41.3" spread="11.29"/>
                    <measurement group_id="B4" value="42.3" spread="13.04"/>
                    <measurement group_id="B5" value="40.4" spread="11.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="168"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 24</title>
        <description>SRI components include:Systemic Lupus Erythematosus Disease Activity Index 2000(SLEDAI-2K),British Isles Lupus Assessment Group(BILAG) 2004,Physician’s Global Assessment(PhGA).Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: greater than or equal to(&gt;=) 4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening (less than [&lt;] 0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids,immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. SLEDAI-2K:assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG:assesses disease extent, severity (range: A[severe] to E[no disease]). PhGA: assesses worsening in participant’s general health status(range: 0[none] to 3[severe]).</description>
        <time_frame>Week 24</time_frame>
        <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Number of participants analyzed= participants who completed through the Week 24 visit. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 24</title>
          <description>SRI components include:Systemic Lupus Erythematosus Disease Activity Index 2000(SLEDAI-2K),British Isles Lupus Assessment Group(BILAG) 2004,Physician’s Global Assessment(PhGA).Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: greater than or equal to(&gt;=) 4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening (less than [&lt;] 0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids,immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. SLEDAI-2K:assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG:assesses disease extent, severity (range: A[severe] to E[no disease]). PhGA: assesses worsening in participant’s general health status(range: 0[none] to 3[severe]).</description>
          <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Number of participants analyzed= participants who completed through the Week 24 visit. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.9"/>
                    <measurement group_id="O2" value="39.2"/>
                    <measurement group_id="O3" value="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Point estimates of the Odds ratio (ORs) as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.076</p_value>
            <p_value_desc>P-value was displayed without adjusting for multiplicity.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>5.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.528</p_value>
            <p_value_desc>P-value was displayed without adjusting for multiplicity.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 4, 8, 12, 16, and 20</title>
        <description>SRI components include:SLEDAI-2K ,BILAG 2004, PhGA. Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: &gt;=4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening (&lt;0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids,immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG:assesses disease extent, severity (range: A [severe] to E [no disease]). PhGA: assesses worsening in participant’s general health status(range: 0[none] to 3[severe]).</description>
        <time_frame>Week 4, 8, 12, 16, 20</time_frame>
        <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 4, 8, 12, 16, and 20</title>
          <description>SRI components include:SLEDAI-2K ,BILAG 2004, PhGA. Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: &gt;=4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening (&lt;0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids,immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG:assesses disease extent, severity (range: A [severe] to E [no disease]). PhGA: assesses worsening in participant’s general health status(range: 0[none] to 3[severe]).</description>
          <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8"/>
                    <measurement group_id="O2" value="21.5"/>
                    <measurement group_id="O3" value="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9"/>
                    <measurement group_id="O2" value="28.9"/>
                    <measurement group_id="O3" value="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7"/>
                    <measurement group_id="O2" value="36.8"/>
                    <measurement group_id="O3" value="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.77</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>12.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.54</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>7.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>2.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>2.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.62</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>4.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 20: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.95</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>4.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 20: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>2.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Modified Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 4, 8, 12, 16, 20, and 24</title>
        <description>SRI components include: modified SLEDAI-2K (SLEDAI-2K without standard parameters &quot;Low complement&quot; and &quot;Leukopenia&quot;), BILAG 2004, PhGA. Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: &gt;=4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening (&lt;0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids, immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. Modified SLEDAI-2K: assesses improvement in disease activity (range: 0 to 102; higher score = higher severity). BILAG: assesses disease extent, severity (range: A [severe] to E [no disease]). PhGA: assesses worsening in participant’s general health status (range: 0[none] to 3[severe]).</description>
        <time_frame>Week 4, 8, 12, 16, 20, 24</time_frame>
        <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Modified Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 4, 8, 12, 16, 20, and 24</title>
          <description>SRI components include: modified SLEDAI-2K (SLEDAI-2K without standard parameters &quot;Low complement&quot; and &quot;Leukopenia&quot;), BILAG 2004, PhGA. Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: &gt;=4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening (&lt;0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids, immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. Modified SLEDAI-2K: assesses improvement in disease activity (range: 0 to 102; higher score = higher severity). BILAG: assesses disease extent, severity (range: A [severe] to E [no disease]). PhGA: assesses worsening in participant’s general health status (range: 0[none] to 3[severe]).</description>
          <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                    <measurement group_id="O2" value="25.7"/>
                    <measurement group_id="O3" value="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6"/>
                    <measurement group_id="O2" value="24.9"/>
                    <measurement group_id="O3" value="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5"/>
                    <measurement group_id="O2" value="46.9"/>
                    <measurement group_id="O3" value="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2"/>
                    <measurement group_id="O2" value="41.4"/>
                    <measurement group_id="O3" value="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>3.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>3.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>2.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.45</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.45</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>3.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 20: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.78</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>4.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 20: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>2.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.22</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>5.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>2.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response at Week 4, 8, 12, 16, 20, and 24</title>
        <description>BICLA include: BILAG-2004, SLEDAI-2K, PhGA of disease activity. Participants classified as responder if they did not meet the definition of treatment failure and met all the following criteria: BILAG-2004 improvement (all A scores at baseline improved to B/C/D and all B scores improved to C or D); no worsening in disease activity (no new BILAG-2004 A scores or =&lt;1 new B score); no worsening of total SLEDAI-2K score; no significant deterioration (&lt;10 percent [%] worsening) in analogue PhGA. Treatment failure: any new/increased use of corticosteroids,immunosuppressants/antimalarial, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. BILAG:assesses disease extent, severity (range: A[severe] to E[no disease]). SLEDAI-2K:assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). PhGA: assesses worsening in participant’s general health status(range: 0[none] to 3[severe]).</description>
        <time_frame>Week 4, 8, 12, 16, 20, 24</time_frame>
        <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response at Week 4, 8, 12, 16, 20, and 24</title>
          <description>BICLA include: BILAG-2004, SLEDAI-2K, PhGA of disease activity. Participants classified as responder if they did not meet the definition of treatment failure and met all the following criteria: BILAG-2004 improvement (all A scores at baseline improved to B/C/D and all B scores improved to C or D); no worsening in disease activity (no new BILAG-2004 A scores or =&lt;1 new B score); no worsening of total SLEDAI-2K score; no significant deterioration (&lt;10 percent [%] worsening) in analogue PhGA. Treatment failure: any new/increased use of corticosteroids,immunosuppressants/antimalarial, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. BILAG:assesses disease extent, severity (range: A[severe] to E[no disease]). SLEDAI-2K:assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). PhGA: assesses worsening in participant’s general health status(range: 0[none] to 3[severe]).</description>
          <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="21.7"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6"/>
                    <measurement group_id="O2" value="39.6"/>
                    <measurement group_id="O3" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5"/>
                    <measurement group_id="O2" value="39.2"/>
                    <measurement group_id="O3" value="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7"/>
                    <measurement group_id="O2" value="31.6"/>
                    <measurement group_id="O3" value="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7"/>
                    <measurement group_id="O2" value="40.5"/>
                    <measurement group_id="O3" value="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>3.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>2.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>3.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.36</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>5.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>4.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 20: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.80</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>7.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 20: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.67</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>4.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.95</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.18</ci_lower_limit>
            <ci_upper_limit>7.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>5.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Pre-defined Criteria for Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Components at Week 24</title>
        <description>SRI components include: SLEDAI-2K, BILAG 2004 and PhGA. Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: &gt;=4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening(&lt;0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids, immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. SLEDAI-2K: assesses improvement in disease activity(range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity (range: A[severe] to E [no disease]). PhGA: assesses worsening in participant’s general health status (range: 0[none] to 3[severe]). Model percent estimates reported only for 'Reduction in SLEDAI Score','No Worsening in PhGA' categories; for remaining categories, raw percentages reported</description>
        <time_frame>Week 24</time_frame>
        <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Number of participants analyzed= participants who completed through the Week 24 visit. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Pre-defined Criteria for Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Components at Week 24</title>
          <description>SRI components include: SLEDAI-2K, BILAG 2004 and PhGA. Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: &gt;=4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening(&lt;0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids, immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. SLEDAI-2K: assesses improvement in disease activity(range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity (range: A[severe] to E [no disease]). PhGA: assesses worsening in participant’s general health status (range: 0[none] to 3[severe]). Model percent estimates reported only for 'Reduction in SLEDAI Score','No Worsening in PhGA' categories; for remaining categories, raw percentages reported</description>
          <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Number of participants analyzed= participants who completed through the Week 24 visit. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 or More Points Reduction in SLEDAI Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7"/>
                    <measurement group_id="O2" value="44.9"/>
                    <measurement group_id="O3" value="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No New 1A/2B BILAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="90.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Worsening in PhGA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4"/>
                    <measurement group_id="O2" value="97.5"/>
                    <measurement group_id="O3" value="93.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>&gt;=4 points reduction in SLEDAI score: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.205</p_value>
            <p_value_desc>P-value was displayed without adjusting for multiplicity.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>4.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>&gt;=4 points reduction in SLEDAI score: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.625</p_value>
            <p_value_desc>P-value was displayed without adjusting for multiplicity.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>2.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No worsening in PhGA: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.198</p_value>
            <p_value_desc>P-value was displayed without adjusting for multiplicity.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.81</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>20.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No worsening in PhGA: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.192</p_value>
            <p_value_desc>P-value was displayed without adjusting for multiplicity.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.88</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>21.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Laboratory Tests Results</title>
        <description>Pre-defined criteria were established for each laboratory test to define the values that would be identified as of potential clinical importance. Laboratory values included Alanine Aminotransferase (ALT) [&gt;5.0 - 10.0*Upper limit of normal range (ULN)], Albumin [&lt;26-20 gram per liter (g/L)/ &lt;20 g/L], Amylase [&gt;2.0 - 5.0*ULN], Aspartate Aminotransferase (AST) [&gt;5.0 - 10.0*ULN], Creatine Kinase (CK) [&gt;5.0 - 10.0* ULN/ &gt;10.0*ULN], Glucose (Hyperglycemia) [&gt;13.9 - 27.8 millimoles/liter (mmol/L)], Hemoglobin (HGB) [&lt;80 - 65 g/L/ &lt;65 g/L], Lipase [&gt;2.0 - 5.0*ULN], Lymphocytes (Lymph.)(Absolute [Abs]) [&lt;0.5 - 0.2*10^3/microliter (UL)/ &lt;0.2*10^3/UL], Platelets [&lt;50-25*10^3/UL/ &lt;25*10^3/UL], potassium (low) [&lt;3.0 - 2.5 mmol/L], Sodium (low) [&lt;130 - 120 mmol/L], Total Neutrophils (TN) (Abs) [&lt;1.0 - 0.5*10^3/UL/ &lt;0.5*10^3/UL], Triglycerides [&gt;5.7 - 11.4 mmol/L], White Blood Cell Count (WBC) [&lt;2.0 - 1.0*10^3/UL/ &lt;1.0*10^3/UL].</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>Safety population defined as all participants who had at least one dose of investigational product. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>PF-04236921 200 mg</title>
            <description>Participants received 200 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Laboratory Tests Results</title>
          <description>Pre-defined criteria were established for each laboratory test to define the values that would be identified as of potential clinical importance. Laboratory values included Alanine Aminotransferase (ALT) [&gt;5.0 - 10.0*Upper limit of normal range (ULN)], Albumin [&lt;26-20 gram per liter (g/L)/ &lt;20 g/L], Amylase [&gt;2.0 - 5.0*ULN], Aspartate Aminotransferase (AST) [&gt;5.0 - 10.0*ULN], Creatine Kinase (CK) [&gt;5.0 - 10.0* ULN/ &gt;10.0*ULN], Glucose (Hyperglycemia) [&gt;13.9 - 27.8 millimoles/liter (mmol/L)], Hemoglobin (HGB) [&lt;80 - 65 g/L/ &lt;65 g/L], Lipase [&gt;2.0 - 5.0*ULN], Lymphocytes (Lymph.)(Absolute [Abs]) [&lt;0.5 - 0.2*10^3/microliter (UL)/ &lt;0.2*10^3/UL], Platelets [&lt;50-25*10^3/UL/ &lt;25*10^3/UL], potassium (low) [&lt;3.0 - 2.5 mmol/L], Sodium (low) [&lt;130 - 120 mmol/L], Total Neutrophils (TN) (Abs) [&lt;1.0 - 0.5*10^3/UL/ &lt;0.5*10^3/UL], Triglycerides [&gt;5.7 - 11.4 mmol/L], White Blood Cell Count (WBC) [&lt;2.0 - 1.0*10^3/UL/ &lt;1.0*10^3/UL].</description>
          <population>Safety population defined as all participants who had at least one dose of investigational product. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin: &lt;26-20 g/L</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin: &lt; 20 g/L</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK: &gt;5.0 -10.0*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK &gt;10.0*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (Hyperglycemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HGB: &lt;80 - 65 g/L</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HGB: &lt;65 g/L</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph.(Abs)&lt;0.5-0.2* 10^3/UL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph.(Abs) &lt;0.2*10^3/UL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets &lt;50 - 25*10^3/UL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets &lt;25*10^3/UL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (low)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (low)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TN (Abs)&lt;1.0-0.5*10^3/UL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TN (Abs) &lt;0.5*10^3/UL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC &lt;2.0 - 1.0*10^3/UL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC &lt;1.0*10^3/UL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued Due to Adverse Events</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Number of participants who discontinued due to adverse events were reported.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>Safety population defined as all participants who had at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>PF-04236921 200 mg</title>
            <description>Participants received 200 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Due to Adverse Events</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Number of participants who discontinued due to adverse events were reported.</description>
          <population>Safety population defined as all participants who had at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 52 that were absent before treatment or that worsened relative to pretreatment state. Number of participants with treatment-emergent AEs or SAEs (excluding infectious AEs or SAEs and injection site reactions) were reported. AEs include both SAEs and non-SAEs.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>Safety population defined as all participants who had at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>PF-04236921 200 mg</title>
            <description>Participants received 200 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 52 that were absent before treatment or that worsened relative to pretreatment state. Number of participants with treatment-emergent AEs or SAEs (excluding infectious AEs or SAEs and injection site reactions) were reported. AEs include both SAEs and non-SAEs.</description>
          <population>Safety population defined as all participants who had at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Infectious Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 52 that were absent before treatment or that worsened relative to pretreatment state. Number of participants with treatment-emergent infectious AEs or SAEs were reported. AEs include both SAEs and non-SAEs.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>Safety population defined as all participants who had at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>PF-04236921 200 mg</title>
            <description>Participants received 200 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Infectious Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 52 that were absent before treatment or that worsened relative to pretreatment state. Number of participants with treatment-emergent infectious AEs or SAEs were reported. AEs include both SAEs and non-SAEs.</description>
          <population>Safety population defined as all participants who had at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infectious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infectious SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Potentially Clinically Important (PCI) Electrocardiogram (ECG) Findings</title>
        <description>Criteria for potentially clinically important (PCI) findings in ECG were defined as: heart rate &lt;=40 beats per minute (bpm) or &gt;=120 bpm; PR interval &gt;=220 millisecond (msec); QT interval &gt;=480 msec; QRS interval &gt;=120 msec; QT interval corrected using the Fridericia formula (QTcF) &gt;=500msec; no sinus rhythm.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>Safety population defined as all participants who had at least one dose of investigational product. Here, N (Number of participants analyzed) signifies participants evaluable for this outcome measure for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>PF-04236921 200 mg</title>
            <description>Participants received 200 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially Clinically Important (PCI) Electrocardiogram (ECG) Findings</title>
          <description>Criteria for potentially clinically important (PCI) findings in ECG were defined as: heart rate &lt;=40 beats per minute (bpm) or &gt;=120 bpm; PR interval &gt;=220 millisecond (msec); QT interval &gt;=480 msec; QRS interval &gt;=120 msec; QT interval corrected using the Fridericia formula (QTcF) &gt;=500msec; no sinus rhythm.</description>
          <population>Safety population defined as all participants who had at least one dose of investigational product. Here, N (Number of participants analyzed) signifies participants evaluable for this outcome measure for each group respectively.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart Rate &lt;=40 beats/min or &gt;=120 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval &gt;=200 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval &gt;=480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Interval &gt;=120 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF &gt;=500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhythm (Not Sinus Rhythm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Potentially Clinically Important Vital Signs Findings</title>
        <description>Criteria for PCI findings in vital signs were defined as: sitting systolic blood pressure (Increase from baseline &gt;=20 millimeter of mercury (mm Hg) and &gt;=160 mm Hg or a decrease from baseline &gt;=20 mm Hg and &lt;=90 mm Hg) and sitting diastolic blood pressure (increase from baseline &gt;=15 mm Hg and &gt;=90 mm Hg or decrease from baseline &gt;=15 mm Hg and &lt;=60 mm Hg), pulse rate (increase from baseline &gt;=15 beats/min and &gt;=120 beats/min or decrease from baseline &gt;=15 beats/min and &lt;=50 beats /min), body temperature (increase of &gt;=2 degree Fahrenheit (F) and temperature &gt;=101 degree F) and weight (change of &gt;=7% in body weight)</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>Safety population defined as all participants who had at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>PF-04236921 200 mg</title>
            <description>Participants received 200 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially Clinically Important Vital Signs Findings</title>
          <description>Criteria for PCI findings in vital signs were defined as: sitting systolic blood pressure (Increase from baseline &gt;=20 millimeter of mercury (mm Hg) and &gt;=160 mm Hg or a decrease from baseline &gt;=20 mm Hg and &lt;=90 mm Hg) and sitting diastolic blood pressure (increase from baseline &gt;=15 mm Hg and &gt;=90 mm Hg or decrease from baseline &gt;=15 mm Hg and &lt;=60 mm Hg), pulse rate (increase from baseline &gt;=15 beats/min and &gt;=120 beats/min or decrease from baseline &gt;=15 beats/min and &lt;=50 beats /min), body temperature (increase of &gt;=2 degree Fahrenheit (F) and temperature &gt;=101 degree F) and weight (change of &gt;=7% in body weight)</description>
          <population>Safety population defined as all participants who had at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sitting Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting Pulse Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-drug Antibodies (ADAs) and Neutralizing Antibodies (Nabs)</title>
        <description>Human serum samples were analyzed for the presence or absence of anti-PF-04236921 antibodies. A positive ADA sample was further tested for neutralizing antibodies using a validated assay.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>Safety population defined as all participants who had at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>PF-04236921 200 mg</title>
            <description>Participants received 200 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-drug Antibodies (ADAs) and Neutralizing Antibodies (Nabs)</title>
          <description>Human serum samples were analyzed for the presence or absence of anti-PF-04236921 antibodies. A positive ADA sample was further tested for neutralizing antibodies using a validated assay.</description>
          <population>Safety population defined as all participants who had at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-drug Antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutralizing Antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentration of PF-04236921</title>
        <description>Serum PF-04236921 concentrations over time were summarized.</description>
        <time_frame>Day 1, Week 2, 4, 6, 8, 12, 16, 20, 24</time_frame>
        <population>Pharmacokinetic analysis set was the subset of participants from safety analysis set (all participants who received at least 1 dose of investigational product) who provided at least 1 pharmacokinetic concentration. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>PF-04236921 200 mg</title>
            <description>Participants received 200 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentration of PF-04236921</title>
          <description>Serum PF-04236921 concentrations over time were summarized.</description>
          <population>Pharmacokinetic analysis set was the subset of participants from safety analysis set (all participants who received at least 1 dose of investigational product) who provided at least 1 pharmacokinetic concentration. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="110.8"/>
                    <measurement group_id="O2" value="31.0" spread="146.9"/>
                    <measurement group_id="O3" value="15.2" spread="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1297" spread="759.4"/>
                    <measurement group_id="O2" value="5640" spread="2274.0"/>
                    <measurement group_id="O3" value="22780" spread="9896.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="991.8" spread="527.6"/>
                    <measurement group_id="O2" value="4337" spread="1495.0"/>
                    <measurement group_id="O3" value="17550" spread="5757.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="608.4" spread="330.1"/>
                    <measurement group_id="O2" value="3396" spread="1410.0"/>
                    <measurement group_id="O3" value="13460" spread="5416.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="463.4" spread="254.9"/>
                    <measurement group_id="O2" value="2709" spread="1317.5"/>
                    <measurement group_id="O3" value="11110" spread="5023.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1210" spread="607.0"/>
                    <measurement group_id="O2" value="6482" spread="2487.4"/>
                    <measurement group_id="O3" value="25240" spread="8114.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="703.2" spread="407.4"/>
                    <measurement group_id="O2" value="3886" spread="1322.1"/>
                    <measurement group_id="O3" value="16990" spread="6203.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1452" spread="726.8"/>
                    <measurement group_id="O2" value="6978" spread="2954.0"/>
                    <measurement group_id="O3" value="31050" spread="11368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="871.9" spread="450.4"/>
                    <measurement group_id="O2" value="4417" spread="2402.4"/>
                    <measurement group_id="O3" value="20150" spread="12091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Corticosteroid Dose Reduced by Both Greater Than or Equal to (&gt;=) 25 Percent (%) From Baseline and Less Than or Equal to (&lt;=) 7.5 Milligrams Per Day (mg/Day)</title>
        <description>Participants were given supplemental corticosteroids at baseline to control disease activity, if necessary. The steroid taper was based on participant’s symptoms. Participants recorded their steroid usage on a diary card. Least Observation Carried Forward (LOCF) method was used to impute missing data.</description>
        <time_frame>Week 12, 16, 20, 24</time_frame>
        <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Number of participants analyzed= participants evaluable for this outcome measure at specified timepoints. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Corticosteroid Dose Reduced by Both Greater Than or Equal to (&gt;=) 25 Percent (%) From Baseline and Less Than or Equal to (&lt;=) 7.5 Milligrams Per Day (mg/Day)</title>
          <description>Participants were given supplemental corticosteroids at baseline to control disease activity, if necessary. The steroid taper was based on participant’s symptoms. Participants recorded their steroid usage on a diary card. Least Observation Carried Forward (LOCF) method was used to impute missing data.</description>
          <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Number of participants analyzed= participants evaluable for this outcome measure at specified timepoints. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="20.8"/>
                    <measurement group_id="O3" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="20.8"/>
                    <measurement group_id="O3" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normalized Serological Activity</title>
        <description>Serologic activity was to be assessed in the subgroup of participants who had positive serologic activity at baseline.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Consistent with the protocol which pre-specified that if the number of participants with abnormal serological activity at baseline were &lt;25% of overall population, data for this outcome measure was not available.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normalized Serological Activity</title>
          <description>Serologic activity was to be assessed in the subgroup of participants who had positive serologic activity at baseline.</description>
          <population>Consistent with the protocol which pre-specified that if the number of participants with abnormal serological activity at baseline were &lt;25% of overall population, data for this outcome measure was not available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Visual Analog Scale (VAS) Scores at Baseline</title>
        <description>Participants assessed their disease activity using a 100 millimeter (mm) VAS. Participants answered the following question “Considering all the ways your disease affects you, how are you feeling today?” Response was recorded by placing a mark on the scale between 0 (very well) and 100 (extremely bad).</description>
        <time_frame>Baseline</time_frame>
        <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Visual Analog Scale (VAS) Scores at Baseline</title>
          <description>Participants assessed their disease activity using a 100 millimeter (mm) VAS. Participants answered the following question “Considering all the ways your disease affects you, how are you feeling today?” Response was recorded by placing a mark on the scale between 0 (very well) and 100 (extremely bad).</description>
          <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.44" spread="2.865"/>
                    <measurement group_id="O2" value="47.70" spread="2.880"/>
                    <measurement group_id="O3" value="49.47" spread="3.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24</title>
        <description>Participants assessed their disease activity using a 100 mm VAS. Participants answered the following question “Considering all the ways your disease affects you, how are you feeling today?” Response was recorded by placing a mark on the scale between 0 (very well) and 100 (extremely bad).</description>
        <time_frame>Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24</time_frame>
        <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24</title>
          <description>Participants assessed their disease activity using a 100 mm VAS. Participants answered the following question “Considering all the ways your disease affects you, how are you feeling today?” Response was recorded by placing a mark on the scale between 0 (very well) and 100 (extremely bad).</description>
          <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.17" lower_limit="-15.09" upper_limit="-3.26"/>
                    <measurement group_id="O2" value="-1.54" lower_limit="-7.22" upper_limit="4.15"/>
                    <measurement group_id="O3" value="-3.58" lower_limit="-9.49" upper_limit="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.24" lower_limit="-9.09" upper_limit="2.62"/>
                    <measurement group_id="O2" value="-4.01" lower_limit="-9.69" upper_limit="1.68"/>
                    <measurement group_id="O3" value="-1.24" lower_limit="-7.02" upper_limit="4.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.48" lower_limit="-11.33" upper_limit="0.37"/>
                    <measurement group_id="O2" value="-3.62" lower_limit="-9.31" upper_limit="2.06"/>
                    <measurement group_id="O3" value="-7.24" lower_limit="-13.02" upper_limit="-1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.17" lower_limit="-10.02" upper_limit="1.68"/>
                    <measurement group_id="O2" value="-6.03" lower_limit="-11.71" upper_limit="-0.34"/>
                    <measurement group_id="O3" value="-7.11" lower_limit="-12.89" upper_limit="-1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.21" lower_limit="-15.07" upper_limit="-3.36"/>
                    <measurement group_id="O2" value="-4.20" lower_limit="-9.88" upper_limit="1.49"/>
                    <measurement group_id="O3" value="-6.88" lower_limit="-12.67" upper_limit="-1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.75" lower_limit="-14.60" upper_limit="-2.89"/>
                    <measurement group_id="O2" value="-10.20" lower_limit="-15.88" upper_limit="-4.51"/>
                    <measurement group_id="O3" value="-5.99" lower_limit="-11.78" upper_limit="-0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.52" lower_limit="-17.38" upper_limit="-5.67"/>
                    <measurement group_id="O2" value="-9.03" lower_limit="-14.71" upper_limit="-3.34"/>
                    <measurement group_id="O3" value="-6.77" lower_limit="-12.56" upper_limit="-0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.17" lower_limit="-15.02" upper_limit="-3.32"/>
                    <measurement group_id="O2" value="-7.45" lower_limit="-13.14" upper_limit="-1.77"/>
                    <measurement group_id="O3" value="-10.64" lower_limit="-16.42" upper_limit="-4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-5.41</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.30</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean difference</param_type>
            <param_value>-1.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.21</ci_lower_limit>
            <ci_upper_limit>5.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean difference</param_type>
            <param_value>1.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.71</ci_lower_limit>
            <ci_upper_limit>8.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean difference</param_type>
            <param_value>4.67</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.22</ci_lower_limit>
            <ci_upper_limit>11.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean difference</param_type>
            <param_value>-3.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.04</ci_lower_limit>
            <ci_upper_limit>3.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean difference</param_type>
            <param_value>-2.89</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.87</ci_lower_limit>
            <ci_upper_limit>4.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 20: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean difference</param_type>
            <param_value>-6.21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.37</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean difference</param_type>
            <param_value>1.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.17</ci_lower_limit>
            <ci_upper_limit>9.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean difference</param_type>
            <param_value>2.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.70</ci_lower_limit>
            <ci_upper_limit>8.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean difference</param_type>
            <param_value>-2.81</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.62</ci_lower_limit>
            <ci_upper_limit>4.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean difference</param_type>
            <param_value>3.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.95</ci_lower_limit>
            <ci_upper_limit>10.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean difference</param_type>
            <param_value>2.56</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.29</ci_lower_limit>
            <ci_upper_limit>9.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean difference</param_type>
            <param_value>3.14</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.67</ci_lower_limit>
            <ci_upper_limit>9.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean difference</param_type>
            <param_value>-4.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.91</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 20: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean difference</param_type>
            <param_value>-2.64</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.61</ci_lower_limit>
            <ci_upper_limit>4.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean difference</param_type>
            <param_value>2.66</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.48</ci_lower_limit>
            <ci_upper_limit>9.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24</title>
        <description>EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point VAS (0= worst imaginable health state, 100= best imaginable health state).</description>
        <time_frame>Baseline, Week 4, 8, 12, 16, 20, 24</time_frame>
        <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24</title>
          <description>EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point VAS (0= worst imaginable health state, 100= best imaginable health state).</description>
          <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" lower_limit="-2.21" upper_limit="8.54"/>
                    <measurement group_id="O2" value="1.45" lower_limit="-3.72" upper_limit="6.62"/>
                    <measurement group_id="O3" value="-0.47" lower_limit="-5.66" upper_limit="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="-0.37" upper_limit="10.38"/>
                    <measurement group_id="O2" value="2.82" lower_limit="-2.28" upper_limit="7.93"/>
                    <measurement group_id="O3" value="7.02" lower_limit="1.83" upper_limit="12.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.47" lower_limit="2.09" upper_limit="12.85"/>
                    <measurement group_id="O2" value="2.51" lower_limit="-2.60" upper_limit="7.61"/>
                    <measurement group_id="O3" value="4.85" lower_limit="-0.35" upper_limit="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.84" lower_limit="1.47" upper_limit="12.22"/>
                    <measurement group_id="O2" value="6.65" lower_limit="1.55" upper_limit="11.76"/>
                    <measurement group_id="O3" value="5.16" lower_limit="-0.04" upper_limit="10.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.68" lower_limit="4.30" upper_limit="15.05"/>
                    <measurement group_id="O2" value="5.19" lower_limit="0.08" upper_limit="10.29"/>
                    <measurement group_id="O3" value="5.09" lower_limit="-0.10" upper_limit="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.33" lower_limit="3.95" upper_limit="14.71"/>
                    <measurement group_id="O2" value="5.04" lower_limit="-0.07" upper_limit="10.14"/>
                    <measurement group_id="O3" value="5.38" lower_limit="0.18" upper_limit="10.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.63</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-2.56</ci_lower_limit>
            <ci_upper_limit>9.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-2.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-8.21</ci_lower_limit>
            <ci_upper_limit>4.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>2.62</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.57</ci_lower_limit>
            <ci_upper_limit>8.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.69</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.51</ci_lower_limit>
            <ci_upper_limit>7.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 20: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>4.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.61</ci_lower_limit>
            <ci_upper_limit>10.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.95</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-2.24</ci_lower_limit>
            <ci_upper_limit>10.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.92</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-4.17</ci_lower_limit>
            <ci_upper_limit>8.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-4.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-10.25</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.50</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.56</ci_lower_limit>
            <ci_upper_limit>7.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 20: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>0.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.96</ci_lower_limit>
            <ci_upper_limit>6.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.39</ci_lower_limit>
            <ci_upper_limit>5.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-2.34</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.39</ci_lower_limit>
            <ci_upper_limit>3.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thirty Six-Item Short-Form Health Survey (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) at Baseline</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as PCS and mental component score MCS. The score for each aspect and PCS/MCS is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.</description>
        <time_frame>Baseline</time_frame>
        <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Number of participants analyzed= participants evaluable for this outcome measure at specified timepoint. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Thirty Six-Item Short-Form Health Survey (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) at Baseline</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as PCS and mental component score MCS. The score for each aspect and PCS/MCS is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.</description>
          <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Number of participants analyzed= participants evaluable for this outcome measure at specified timepoint. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.50" spread="1.810"/>
                    <measurement group_id="O2" value="42.36" spread="1.426"/>
                    <measurement group_id="O3" value="39.94" spread="1.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.47" spread="1.169"/>
                    <measurement group_id="O2" value="34.36" spread="1.250"/>
                    <measurement group_id="O3" value="34.64" spread="1.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical component score (PCS) and mental component score (MCS). The score for each aspect and PCS/MCS is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.</description>
        <time_frame>Baseline, Week 4, 8, 12, 16, 20, 24</time_frame>
        <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical component score (PCS) and mental component score (MCS). The score for each aspect and PCS/MCS is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.</description>
          <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCS: Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" lower_limit="-0.69" upper_limit="4.64"/>
                    <measurement group_id="O2" value="1.45" lower_limit="-1.14" upper_limit="4.04"/>
                    <measurement group_id="O3" value="1.45" lower_limit="-1.12" upper_limit="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS: Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" lower_limit="-1.10" upper_limit="4.23"/>
                    <measurement group_id="O2" value="1.97" lower_limit="-0.59" upper_limit="4.52"/>
                    <measurement group_id="O3" value="2.05" lower_limit="-0.52" upper_limit="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" lower_limit="1.13" upper_limit="6.46"/>
                    <measurement group_id="O2" value="2.50" lower_limit="-0.06" upper_limit="5.05"/>
                    <measurement group_id="O3" value="2.52" lower_limit="-0.05" upper_limit="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS: Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.73" lower_limit="2.07" upper_limit="7.40"/>
                    <measurement group_id="O2" value="2.79" lower_limit="0.24" upper_limit="5.35"/>
                    <measurement group_id="O3" value="2.95" lower_limit="0.38" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS: Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.49" lower_limit="1.82" upper_limit="7.15"/>
                    <measurement group_id="O2" value="1.71" lower_limit="-0.85" upper_limit="4.26"/>
                    <measurement group_id="O3" value="3.28" lower_limit="0.71" upper_limit="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" lower_limit="0.28" upper_limit="5.60"/>
                    <measurement group_id="O2" value="2.14" lower_limit="-0.41" upper_limit="4.70"/>
                    <measurement group_id="O3" value="2.85" lower_limit="0.28" upper_limit="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS: Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.95" lower_limit="1.75" upper_limit="6.15"/>
                    <measurement group_id="O2" value="3.24" lower_limit="1.10" upper_limit="5.38"/>
                    <measurement group_id="O3" value="1.28" lower_limit="-0.85" upper_limit="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS: Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.48" lower_limit="3.27" upper_limit="7.68"/>
                    <measurement group_id="O2" value="4.79" lower_limit="2.68" upper_limit="6.90"/>
                    <measurement group_id="O3" value="2.11" lower_limit="-0.01" upper_limit="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.06" lower_limit="3.86" upper_limit="8.26"/>
                    <measurement group_id="O2" value="4.66" lower_limit="2.55" upper_limit="6.77"/>
                    <measurement group_id="O3" value="2.82" lower_limit="0.70" upper_limit="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS: Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25" lower_limit="4.05" upper_limit="8.45"/>
                    <measurement group_id="O2" value="4.50" lower_limit="2.39" upper_limit="6.61"/>
                    <measurement group_id="O3" value="2.48" lower_limit="0.36" upper_limit="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS: Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" lower_limit="4.19" upper_limit="8.59"/>
                    <measurement group_id="O2" value="5.63" lower_limit="3.52" upper_limit="7.74"/>
                    <measurement group_id="O3" value="3.29" lower_limit="1.17" upper_limit="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" lower_limit="3.77" upper_limit="8.18"/>
                    <measurement group_id="O2" value="5.53" lower_limit="3.42" upper_limit="7.64"/>
                    <measurement group_id="O3" value="2.94" lower_limit="0.82" upper_limit="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 4: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>0.53</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.53</ci_lower_limit>
            <ci_upper_limit>3.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.54</ci_lower_limit>
            <ci_upper_limit>2.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.78</ci_lower_limit>
            <ci_upper_limit>4.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.78</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>4.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.86</ci_lower_limit>
            <ci_upper_limit>4.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>0.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.98</ci_lower_limit>
            <ci_upper_limit>3.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 4: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>0.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.03</ci_lower_limit>
            <ci_upper_limit>3.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.09</ci_lower_limit>
            <ci_upper_limit>2.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.03</ci_lower_limit>
            <ci_upper_limit>2.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-0.16</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.17</ci_lower_limit>
            <ci_upper_limit>2.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-1.58</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.58</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-0.71</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.72</ci_lower_limit>
            <ci_upper_limit>2.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 4: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>2.67</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>5.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.36</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>5.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>5.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.77</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.24</ci_lower_limit>
            <ci_upper_limit>6.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>5.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>5.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 4: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>4.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>2.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>5.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.84</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>4.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>2.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>4.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>2.34</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>4.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>2.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>5.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vitality Scores at Week 4, 8, 12, 16, 20 and 24</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Vitality sub-score is a component of SF-36 Health Survey Questionnaire and assesses energy and fatigue. The vitality score ranged from 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.</description>
        <time_frame>Baseline, Week 4, 8, 12, 16, 20, 24</time_frame>
        <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vitality Scores at Week 4, 8, 12, 16, 20 and 24</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Vitality sub-score is a component of SF-36 Health Survey Questionnaire and assesses energy and fatigue. The vitality score ranged from 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.</description>
          <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" lower_limit="-2.00" upper_limit="9.83"/>
                    <measurement group_id="O2" value="4.78" lower_limit="-0.97" upper_limit="10.52"/>
                    <measurement group_id="O3" value="3.45" lower_limit="-2.27" upper_limit="9.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.53" lower_limit="0.62" upper_limit="12.45"/>
                    <measurement group_id="O2" value="6.55" lower_limit="0.87" upper_limit="12.23"/>
                    <measurement group_id="O3" value="2.61" lower_limit="-3.10" upper_limit="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.75" lower_limit="4.83" upper_limit="16.66"/>
                    <measurement group_id="O2" value="6.41" lower_limit="0.74" upper_limit="12.09"/>
                    <measurement group_id="O3" value="7.19" lower_limit="1.48" upper_limit="12.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.60" lower_limit="4.69" upper_limit="16.52"/>
                    <measurement group_id="O2" value="6.41" lower_limit="0.74" upper_limit="12.09"/>
                    <measurement group_id="O3" value="2.75" lower_limit="-2.97" upper_limit="8.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.91" lower_limit="5.99" upper_limit="17.82"/>
                    <measurement group_id="O2" value="7.78" lower_limit="2.10" upper_limit="13.45"/>
                    <measurement group_id="O3" value="4.79" lower_limit="-0.93" upper_limit="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.58" lower_limit="3.66" upper_limit="15.49"/>
                    <measurement group_id="O2" value="6.69" lower_limit="1.01" upper_limit="12.37"/>
                    <measurement group_id="O3" value="5.25" lower_limit="-0.47" upper_limit="10.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>0.47</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-6.33</ci_lower_limit>
            <ci_upper_limit>7.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.92</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-2.88</ci_lower_limit>
            <ci_upper_limit>10.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.55</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.25</ci_lower_limit>
            <ci_upper_limit>10.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>7.85</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>14.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>7.12</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>13.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>4.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.47</ci_lower_limit>
            <ci_upper_limit>11.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.40</ci_lower_limit>
            <ci_upper_limit>8.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.93</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.75</ci_lower_limit>
            <ci_upper_limit>10.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-0.78</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.47</ci_lower_limit>
            <ci_upper_limit>5.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.67</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-3.02</ci_lower_limit>
            <ci_upper_limit>10.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>2.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.70</ci_lower_limit>
            <ci_upper_limit>9.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.44</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.24</ci_lower_limit>
            <ci_upper_limit>8.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24</title>
        <description>The SF-6D focuses on seven of the eight health domains covered by the SF-36 Health Survey: physical functioning, role participation (combined role-physical and role-emotional), social functioning, bodily pain, mental health, and vitality. The SF-6D is an attempt to derive a single index from the SF-36 Health Survey for use in economic evaluation studies. As such, it represents a summary score based on a subset of the SF-36 data. Consequently, in lieu of the SF-6D, PCS and MCS SF-36 results are being provided. The score for each aspect and PCS/MCS is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.</description>
        <time_frame>Baseline, Week 4, 8, 12, 16, 20, 24</time_frame>
        <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24</title>
          <description>The SF-6D focuses on seven of the eight health domains covered by the SF-36 Health Survey: physical functioning, role participation (combined role-physical and role-emotional), social functioning, bodily pain, mental health, and vitality. The SF-6D is an attempt to derive a single index from the SF-36 Health Survey for use in economic evaluation studies. As such, it represents a summary score based on a subset of the SF-36 data. Consequently, in lieu of the SF-6D, PCS and MCS SF-36 results are being provided. The score for each aspect and PCS/MCS is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.</description>
          <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCS: Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" lower_limit="-0.69" upper_limit="4.64"/>
                    <measurement group_id="O2" value="1.45" lower_limit="-1.14" upper_limit="4.04"/>
                    <measurement group_id="O3" value="1.45" lower_limit="-1.12" upper_limit="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS: Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" lower_limit="-1.10" upper_limit="4.23"/>
                    <measurement group_id="O2" value="1.97" lower_limit="-0.59" upper_limit="4.52"/>
                    <measurement group_id="O3" value="2.05" lower_limit="-0.52" upper_limit="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" lower_limit="1.13" upper_limit="6.46"/>
                    <measurement group_id="O2" value="2.50" lower_limit="-0.06" upper_limit="5.05"/>
                    <measurement group_id="O3" value="2.52" lower_limit="-0.05" upper_limit="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS: Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.73" lower_limit="2.07" upper_limit="7.40"/>
                    <measurement group_id="O2" value="2.79" lower_limit="0.24" upper_limit="5.35"/>
                    <measurement group_id="O3" value="2.95" lower_limit="0.38" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS: Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.49" lower_limit="1.82" upper_limit="7.15"/>
                    <measurement group_id="O2" value="1.71" lower_limit="-0.85" upper_limit="4.26"/>
                    <measurement group_id="O3" value="3.28" lower_limit="0.71" upper_limit="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" lower_limit="0.28" upper_limit="5.60"/>
                    <measurement group_id="O2" value="2.14" lower_limit="-0.41" upper_limit="4.70"/>
                    <measurement group_id="O3" value="2.85" lower_limit="0.28" upper_limit="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS: Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.95" lower_limit="1.75" upper_limit="6.15"/>
                    <measurement group_id="O2" value="3.24" lower_limit="1.10" upper_limit="5.38"/>
                    <measurement group_id="O3" value="1.28" lower_limit="-0.85" upper_limit="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS: Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.48" lower_limit="3.27" upper_limit="7.68"/>
                    <measurement group_id="O2" value="4.79" lower_limit="2.68" upper_limit="6.90"/>
                    <measurement group_id="O3" value="2.11" lower_limit="-0.01" upper_limit="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.06" lower_limit="3.86" upper_limit="8.26"/>
                    <measurement group_id="O2" value="4.66" lower_limit="2.55" upper_limit="6.77"/>
                    <measurement group_id="O3" value="2.82" lower_limit="0.70" upper_limit="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS: Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25" lower_limit="4.05" upper_limit="8.45"/>
                    <measurement group_id="O2" value="4.50" lower_limit="2.39" upper_limit="6.61"/>
                    <measurement group_id="O3" value="2.48" lower_limit="0.36" upper_limit="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS: Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" lower_limit="4.19" upper_limit="8.59"/>
                    <measurement group_id="O2" value="5.63" lower_limit="3.52" upper_limit="7.74"/>
                    <measurement group_id="O3" value="3.29" lower_limit="1.17" upper_limit="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" lower_limit="3.77" upper_limit="8.18"/>
                    <measurement group_id="O2" value="5.53" lower_limit="3.42" upper_limit="7.64"/>
                    <measurement group_id="O3" value="2.94" lower_limit="0.82" upper_limit="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 4: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>0.53</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.53</ci_lower_limit>
            <ci_upper_limit>3.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.54</ci_lower_limit>
            <ci_upper_limit>2.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.78</ci_lower_limit>
            <ci_upper_limit>4.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.78</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>4.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.86</ci_lower_limit>
            <ci_upper_limit>4.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>0.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.98</ci_lower_limit>
            <ci_upper_limit>3.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 4: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>0.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.03</ci_lower_limit>
            <ci_upper_limit>3.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.09</ci_lower_limit>
            <ci_upper_limit>2.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.03</ci_lower_limit>
            <ci_upper_limit>2.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-0.16</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.17</ci_lower_limit>
            <ci_upper_limit>2.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-1.58</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.58</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>-0.71</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.72</ci_lower_limit>
            <ci_upper_limit>2.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 4: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>2.67</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>5.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.36</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>5.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>5.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.77</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.24</ci_lower_limit>
            <ci_upper_limit>6.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>5.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>5.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 4: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>4.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>2.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>5.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.84</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>4.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>2.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>4.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>2.34</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>4.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>2.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>5.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) Score at Baseline</title>
        <description>FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant’s response to the questions (with the exception of 2 negatively stated), greater was the participant’s fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant’s response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).</description>
        <time_frame>Baseline</time_frame>
        <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) Score at Baseline</title>
          <description>FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant’s response to the questions (with the exception of 2 negatively stated), greater was the participant’s fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant’s response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).</description>
          <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.91" spread="1.700"/>
                    <measurement group_id="O2" value="29.38" spread="1.506"/>
                    <measurement group_id="O3" value="25.96" spread="1.760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24</title>
        <description>FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant’s response to the questions (with the exception of 2 negatively stated), greater was the participant’s fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant’s response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). LOCF method was used to impute missing values.</description>
        <time_frame>Baseline, Week 4, 8, 12, 16, 20, 24</time_frame>
        <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04236921 10 Milligram (10 mg)</title>
            <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O2">
            <title>PF-04236921 50 mg</title>
            <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24</title>
          <description>FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant’s response to the questions (with the exception of 2 negatively stated), greater was the participant’s fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant’s response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). LOCF method was used to impute missing values.</description>
          <population>Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies those participants who were evaluable at specified time points. As per sponsor’s decision, dosing in “PF-04236921 200 mg” arm was prematurely terminated and hence it was not included in efficacy analysis.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" lower_limit="0.25" upper_limit="6.07"/>
                    <measurement group_id="O2" value="2.77" lower_limit="-0.05" upper_limit="5.60"/>
                    <measurement group_id="O3" value="1.08" lower_limit="-1.72" upper_limit="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" lower_limit="1.49" upper_limit="7.30"/>
                    <measurement group_id="O2" value="3.41" lower_limit="0.62" upper_limit="6.20"/>
                    <measurement group_id="O3" value="2.44" lower_limit="-0.37" upper_limit="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" lower_limit="2.16" upper_limit="7.97"/>
                    <measurement group_id="O2" value="3.59" lower_limit="0.80" upper_limit="6.38"/>
                    <measurement group_id="O3" value="2.26" lower_limit="-0.54" upper_limit="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.81" lower_limit="2.90" upper_limit="8.72"/>
                    <measurement group_id="O2" value="5.53" lower_limit="2.74" upper_limit="8.32"/>
                    <measurement group_id="O3" value="1.93" lower_limit="-0.88" upper_limit="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.37" lower_limit="2.46" upper_limit="8.28"/>
                    <measurement group_id="O2" value="4.32" lower_limit="1.53" upper_limit="7.11"/>
                    <measurement group_id="O3" value="3.42" lower_limit="0.61" upper_limit="6.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" lower_limit="1.49" upper_limit="7.30"/>
                    <measurement group_id="O2" value="3.30" lower_limit="0.51" upper_limit="6.09"/>
                    <measurement group_id="O3" value="2.70" lower_limit="-0.10" upper_limit="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4: Analysis was done using the ANCOVA model; CI parameter being the Least Square (LS) mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>2.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.26</ci_lower_limit>
            <ci_upper_limit>5.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.95</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.38</ci_lower_limit>
            <ci_upper_limit>5.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>2.81</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>6.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.88</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>7.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.95</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>5.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.69</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.65</ci_lower_limit>
            <ci_upper_limit>5.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.69</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.61</ci_lower_limit>
            <ci_upper_limit>4.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>0.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.31</ci_lower_limit>
            <ci_upper_limit>4.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>1.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.96</ci_lower_limit>
            <ci_upper_limit>4.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>3.60</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>6.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>0.91</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.38</ci_lower_limit>
            <ci_upper_limit>4.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS mean difference</param_type>
            <param_value>0.60</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.68</ci_lower_limit>
            <ci_upper_limit>3.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>An AE may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study. SAEs consist of all the SAEs including infectious SAEs; non-SAEs consist of all the non-SAEs including infectious non-SAEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>PF-04236921 10 Milligram (10 mg)</title>
          <description>Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
        </group>
        <group group_id="E2">
          <title>PF-04236921 50 mg</title>
          <description>Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
        </group>
        <group group_id="E3">
          <title>PF-04236921 200 mg</title>
          <description>Participants received 200 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardio</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Latent tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arthroscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vasculitis cerebral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Ovarian haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

